CoChat
Sign Up
Cited by 64

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Triptolide delivery: Nanotechnology-based carrier systems to enhance efficacy and limit toxicity

Ren, Qing, Li, Meimei, Deng, Yun, Lu, Aiping, Lu, Jun·2021·Pharmacological Research
DOI 10.1016/j.phrs.2020.105377
Open this paper in CoChat — free account

Abstract

Triptolide (TP) possesses a wide range of biological and pharmacological activities involved in the treatment of various diseases. However, widespread usages of TP raise the urgent issues of the severe toxicity, which hugely limits its further clinical application. The novel functional nanostructured delivery system, which is of great significance in enhancing the efficacy, reducing side effects and improving bioavailability, could improve the enrichment, penetration and controlled release of drugs in the lesion location. Over the past decades, considerable efforts have been dedicated to designing and developing a variety of TP delivery systems with the intention of alleviating the adverse toxicity effects and enhancing the bioavailability. In this review, we briefly summarized and discussed the recent functionalized nano-TP delivery systems for the momentous purpose of guiding further development of novel TP delivery systems and providing perspectives for future clinical applications.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2020.105377

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 96

  1. Morris, 1972, Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii, J Am Chem Soc, 94, 7194, 10.1021/ja00775a078 · DOI
  2. Brinker, 2007, Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae), Phytochemistry, 68, 732, 10.1016/j.phytochem.2006.11.029 · DOI
  3. Gu, 2016, Triptolide reduces the required dose of tacrolimus by attenuating inflammation, enhancing immunosuppression, and increasing donor chimerism in a heterotopic hindlimb transplantation model, Plast. Reconstr. Surg., 138, 1243, 10.1097/PRS.0000000000002770 · DOI
  4. Tasneem, 2019, Molecular pharmacology of inflammation: medicinal plants as anti-inflammatory agents, Pharmacol. Res., 139, 126, 10.1016/j.phrs.2018.11.001 · DOI · Paper page
  5. Xi, 2017, Toxicity of triptolide and the molecular mechanisms involved, Biomed. Pharmacother., 90, 531, 10.1016/j.biopha.2017.04.003 · DOI
  6. Song, 2018, Preclinical pharmacokinetics of triptolide: a potential antitumor drug, Curr. Drug Metab.
  7. Zhou, 2014, Triptolide-induced oxidative stress involved with Nrf2 contribute to cardiomyocyte apoptosis through mitochondrial dependent pathways, Toxicol. Lett., 230, 454, 10.1016/j.toxlet.2014.08.017 · DOI
  8. Li, 2017, Quantitative proteomics and targeted fatty acids analysis reveal the damage of triptolide in liver and kidney, Proteomics, 17, 10.1002/pmic.201700001 · DOI
  9. Huang, 2020, Gut microbiota protects from triptolide-induced hepatotoxicity: key role of propionate and its downstream signalling events, Pharmacol. Res., 10.1016/j.phrs.2020.104752 · DOI
  10. Xue, 2012, Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats, Eur. J. Pharm. Sci., 47, 713, 10.1016/j.ejps.2012.05.012 · DOI
  11. Gong, 2015, Absorption and metabolism characteristics of triptolide as determined by a sensitive and reliable LC-MS/MS method, Molecules, 20, 8928, 10.3390/molecules20058928 · DOI
  12. Yao, 2008, Involvement of mitochondrial pathway in triptolide-induced cytotoxicity in human normal liver L-02 cells, Biol. Pharm. Bull., 31, 592, 10.1248/bpb.31.592 · DOI
  13. He, 2015, Covalent modification of a cysteine residue in the XPB subunit of the general transcription factor TFIIH through single epoxide cleavage of the transcription inhibitor triptolide, Angew. Chemie Int. Ed., 54, 1859, 10.1002/anie.201408817 · DOI
  14. Yi, 2016, Triptolide induces cell killing in multidrug-resistant tumor cells via CDK7/RPB1 rather than XPB or p44, Mol. Cancer Ther., 15, 1495, 10.1158/1535-7163.MCT-15-0753 · DOI
  15. Hu, 2018, Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis, Oncol. Rep., 39, 1191
  16. Liu, 2011, Triptolide and its expanding multiple pharmacological functions, Int. Immunopharmacol., 11, 377, 10.1016/j.intimp.2011.01.012 · DOI
  17. Titov, 2011, XPB, a subunit of TFIIH, is a target of the natural product triptolide, Nat. Chem. Biol., 7, 182, 10.1038/nchembio.522 · DOI
  18. Li, 2012, Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo, Cancer Lett., 319, 203, 10.1016/j.canlet.2012.01.006 · DOI
  19. Cai, 2013, Combined effects of curcumin and triptolide on an ovarian cancer cell line, Asian Pacific J. Cancer Prev., 14, 4267, 10.7314/APJCP.2013.14.7.4267 · DOI
  20. Alsaied, 2014, Sorafenib and triptolide as combination therapy for hepatocellular carcinoma, Surgery, 156, 270, 10.1016/j.surg.2014.04.055 · DOI
  21. Liu, 2013, Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors, Cell Death Dis., 4, e948, 10.1038/cddis.2013.467 · DOI
  22. Kiviharju, 2002, Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells, Clin. Cancer Res., 8, 2666
  23. Noel, 2019, Triptolide and its derivatives as cancer therapies, Trends Pharmacol. Sci., 40, 327, 10.1016/j.tips.2019.03.002 · DOI · Paper page
  24. Lawrence, 2000, Microemulsion-based media as novel drug delivery systems, Adv. Drug Deliv. Rev., 45, 89, 10.1016/S0169-409X(00)00103-4 · DOI
  25. Wissing, 2004, Solid lipid nanoparticles for parenteral drug delivery, Adv. Drug Deliv. Rev., 56, 1257, 10.1016/j.addr.2003.12.002 · DOI
  26. Torchilin, 2006, Multifunctional nanocarriers, Adv. Drug Deliv. Rev., 58, 1532, 10.1016/j.addr.2006.09.009 · DOI
  27. Kamaly, 2012, Targeted polymeric therapeutic nanoparticles: design, development and clinical translation, Chem. Soc. Rev., 41, 2971, 10.1039/c2cs15344k · DOI
  28. Zhou, 2012, Triptolide: structural modifications, structure–activity relationships, bioactivities, clinical development and mechanisms, Nat. Prod. Rep., 29, 457, 10.1039/c2np00088a · DOI
  29. Wu, 2011, Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway, Oncol. Rep., 25, 551
  30. Zhuang, 2013, Assessment of the roles of P-glycoprotein and cytochrome P450 in triptolide-induced liver toxicity in sandwich-cultured rat hepatocyte model, Drug Metab. Dispos., 10.1124/dmd.113.054056 · DOI
  31. Müller, 2000, Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art, Eur. J. Pharm. Biopharm., 50, 161, 10.1016/S0939-6411(00)00087-4 · DOI
  32. Geszke-Moritz, 2016, Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies, Mater. Sci. Eng. C, 68, 982, 10.1016/j.msec.2016.05.119 · DOI
  33. Mei, 2003, Solid lipid nanoparticle and microemulsion for topical delivery of triptolide, Eur. J. Pharm. Biopharm., 56, 189, 10.1016/S0939-6411(03)00067-5 · DOI
  34. Mei, 2005, The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle, Pharmacol. Res., 51, 345, 10.1016/j.phrs.2004.10.007 · DOI
  35. Mei, 2005, Triptolide loaded solid lipid nanoparticle hydrogel for topical application, Drug Dev. Ind. Pharm., 31, 161, 10.1081/DDC-200047791 · DOI
  36. Ni, 2008, Male reproductive toxicity and toxicokinetics of triptolide in rats, Arzneimittelforschung, 58, 673
  37. Zhang, 2013, Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation, Molecules, 18, 13340, 10.3390/molecules181113340 · DOI
  38. Shao, 2007, Pharmacokinetic study of triptolide, a constituent of immunosuppressive Chinese herb medicine, in rats, Biol. Pharm. Bull., 30, 702, 10.1248/bpb.30.702 · DOI
  39. Mao, 1999, Pharmacokinetics of triptolide. Development and application of a high performance liquid chromatographic method for quantitation of triptolide in plasma, J. Liq. Chromatogr. Relat. Technol., 22, 1355, 10.1081/JLC-100101737 · DOI
  40. Zhang, 2014, Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats, Int. J. Nanomed. Nanosurg., 9, 1049
  41. Gu, 2018, Lipid nanoparticles loading triptolide for transdermal delivery: mechanisms of penetration enhancement and transport properties, Int. J. Nanobiotechnology Pharm., 16, 68, 10.1186/s12951-018-0389-3 · DOI · Paper page
  42. Li, 2016, Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas, Drug Deliv., 23, 1344, 10.3109/10717544.2015.1028603 · DOI
  43. Gu, 2019, Transdermal drug delivery of triptolide-loaded nanostructured lipid carriers: preparation, pharmacokinetic, and evaluation for rheumatoid arthritis, Int J Pharmaceut, 554, 235, 10.1016/j.ijpharm.2018.11.024 · DOI
  44. Akbarzadeh, 2013, Liposome: classification, preparation, and applications, Nanoscale Res. Lett., 8, 102, 10.1186/1556-276X-8-102 · DOI
  45. Hua, 2013, The use of lipid-based nanocarriers for targeted pain therapies, Front. Pharmacol., 4, 143, 10.3389/fphar.2013.00143 · DOI
  46. Metselaar, 2005, Liposomes in the treatment of inflammatory disorders, Expert Opin. Drug Deliv., 2, 465, 10.1517/17425247.2.3.465 · DOI
  47. Monteiro, 2014, Liposomes in tissue engineering and regenerative medicine, J. R. Soc. Interface, 11, 10.1098/rsif.2014.0459 · DOI
  48. Dasa, 2015, Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction, J. Control. Release, 220, 556, 10.1016/j.jconrel.2015.06.017 · DOI
  49. Caracciolo, 2015, Liposome–protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines, Nanomed. Nanotechnol. Biol. Med., 11, 543, 10.1016/j.nano.2014.11.003 · DOI
  50. Chen, 2010, Preparation and anti-inflammatory activity of triptolide ethosomes in an erythema model, J. Liposome Res., 20, 297, 10.3109/08982100903544144 · DOI
  51. Xing-yao, 2007, Preparation of triptolide-liposome and its in vivo antitumor activity, Chin. J. Modern Appl. Pharm., 4
  52. Yuan, 2017, Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes, Int. J. Nanomed. Nanosurg., 12, 5673, 10.2147/IJN.S141095 · DOI
  53. Lin, 2017, Pulmonary delivery of triptolide-loaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy, Sci Rep-Uk, 7, 1
  54. Lin, 2018, Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide, Drug Deliv., 25, 256, 10.1080/10717544.2018.1425777 · DOI
  55. Zheng, 2019, Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity, Int J Pharmaceut, 572, 10.1016/j.ijpharm.2019.118721 · DOI
  56. Gaucher, 2005, Block copolymer micelles: preparation, characterization and application in drug delivery, J. Control. Release, 109, 169, 10.1016/j.jconrel.2005.09.034 · DOI · Paper page
  57. Danhier, 2015, Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors, Int. J. Pharmaceut., 479, 399, 10.1016/j.ijpharm.2015.01.009 · DOI
  58. Bölgen, 2018, Biodegradable polymeric micelles for drug delivery applications, Vol. 1, 635
  59. Liu, 2005, Characterization and release of triptolide-loaded poly (D, L-lactic acid) nanoparticles, Eur. Polym. J., 41, 375, 10.1016/j.eurpolymj.2004.09.015 · DOI
  60. Liu, 2005, Anti-inflammatory effects of triptolide loaded poly (D, L-lactic acid) nanoparticles on adjuvant-induced arthritis in rats, J. Ethnopharmacol., 97, 219, 10.1016/j.jep.2004.10.031 · DOI
  61. Liu, 2008, Preliminary research on abating rat testicle toxicity due to triptolide after oral polymer nanoparticle delivery, Drug Discov. Ther., 2, 188
  62. Liu, 2008, Effect of poly (D, L-lactic acid) nanoparticles as triptolide carrier on abating rats renal toxicity by NMR-based metabolic analysis, J Nanosci Nanotechno, 8, 3493, 10.1166/jnn.2008.136 · DOI
  63. Xu, 2008, Anti-tumour and immuno-modulation effects of triptolide-loaded polymeric micelles, Eur. J. Pharm. Biopharm., 70, 741, 10.1016/j.ejpb.2008.07.017 · DOI
  64. Zheng, 2011, Cytotoxicity of Triptolide and Triptolide loaded polymeric micelles in vitro, Toxicol. In Vitro, 25, 1557, 10.1016/j.tiv.2011.05.020 · DOI
  65. Xu, 2013, Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents, Food Chem. Toxicol., 57, 371, 10.1016/j.fct.2013.03.044 · DOI
  66. Ding, 2012, Molecular engineered super‐nanodevices: smart and safe delivery of potent drugs into tumors, Adv. Mater., 24, 3639, 10.1002/adma.201200954 · DOI
  67. Ling, 2014, pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma, ACS Nano, 8, 8027, 10.1021/nn502074x · DOI
  68. Wang, 2015, Inhibition of cancer angiogenesis using triptolide nanoparticles, J. Biomed. Nanotechnol., 11, 805, 10.1166/jbn.2015.2016 · DOI
  69. Zhang, 2016, Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo, Int. J. Nanomed. Nanosurg., 11, 2663
  70. Wang, 2016, Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine, Oncotarget, 7, 8360, 10.18632/oncotarget.7073 · DOI · Paper page
  71. Zhang, 2018, Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis, Int. J. Nanomed. Nanosurg., 13, 2051, 10.2147/IJN.S151233 · DOI
  72. Xu, 2018, Ph-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy, Int. J. Nanomed. Nanosurg., 13, 7229, 10.2147/IJN.S182197 · DOI
  73. Tenjarla, 1999, Microemulsions: an overview and pharmaceutical applications, Crit. Rev. Ther. Drug Carrier Syst., 16, 10.1615/CritRevTherDrugCarrierSyst.v16.i5.20 · DOI
  74. Salvia-Trujillo, 2017, Edible nanoemulsions as carriers of active ingredients: a review, Annu. Rev. Food Sci. Technol., 8, 439, 10.1146/annurev-food-030216-025908 · DOI
  75. Chen, 2004, A study of microemulsion systems for transdermal delivery of triptolide, J. Control. Release, 98, 427, 10.1016/j.jconrel.2004.06.001 · DOI
  76. Xu, 2008, In vivo evaluation of the safety of triptolide-loaded hydrogel-thickened microemulsion, Food Chem. Toxicol., 46, 3792, 10.1016/j.fct.2008.09.065 · DOI
  77. Yang, 2017, Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics, Int. J. Nanobiotechnology Pharm., 15, 88, 10.1186/s12951-017-0323-0 · DOI
  78. Chen, 2015, The potential of follicle-stimulating hormone peptide-modified triptolide-loaded nanoparticles to induce a mouse model of premature ovarian insufficiency, Int. J. Nanomed. Nanosurg., 10, 2765, 10.2147/IJN.S72593 · DOI
  79. Ding, 2017, Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells, Nanoscale, 9, 11739, 10.1039/C7NR03016A · DOI
  80. Seib, 2013, pH‐dependent anticancer drug release from silk nanoparticles, Adv. Healthc. Mater., 2, 1606, 10.1002/adhm.201300034 · DOI
  81. Wang, 2018, Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatment, Sci Rep-Uk, 8, 12968, 10.1038/s41598-018-29692-0 · DOI
  82. Hughes, 2017, Glutathione and glutathione transferase omega 1 as key posttranslational regulators in macrophages, Microbiol. Spectr., 5, 10.1128/microbiolspec.MCHD-0044-2016 · DOI
  83. Shan, 2019, Cubic and hexagonal liquid crystals as drug carriers for the transdermal delivery of triptolide, Drug Deliv., 26, 490, 10.1080/10717544.2019.1602796 · DOI
  84. Zabara, 2014, Controlling molecular transport and sustained drug release in lipid-based liquid crystalline mesophases, J. Control. Release, 188, 31, 10.1016/j.jconrel.2014.05.052 · DOI
  85. Wang, 2017, Polo-like kinase 1-targeting Chitosan Nanoparticles suppress the progression of hepatocellular carcinoma, Anti-Cancer Agents Med. Chem., 17, 948, 10.2174/1871520616666160926111911 · DOI
  86. Huang, 2017, In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy, Drug Deliv., 24, 459, 10.1080/10717544.2016.1264499 · DOI
  87. Zhang, 2019, Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms, Nanomed. Nanotechnol. Biol. Med., 15, 86, 10.1016/j.nano.2018.09.002 · DOI
  88. Liu, 2020, Self-assembled casein nanoparticles loading triptolide for the enhancement of oral bioavailability, Nat. Prod. Commun., 15
  89. Tian, 2018, Synthesis, characterization, and evaluation of triptolide cell-penetrating peptide derivative for transdermal delivery of triptolide, J. Mol. Pharm. Org. Process Res., 15, 560
  90. Shi, 2012, Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage, Int. J. Nanomed. Nanosurg., 7, 1613
  91. Miller, 2013, Premature drug release of polymeric micelles and its effects on tumor targeting, Int. J. Pharmaceut., 445, 117, 10.1016/j.ijpharm.2013.01.059 · DOI
  92. Lu, 2016, Linkers having a crucial role in antibody–drug conjugates, Int. J. Mol. Sci., 17, 561, 10.3390/ijms17040561 · DOI
  93. Hu, 2016, Anti-cancer and sensibilisation effect of triptolide on human epithelial ovarian cancer, J. Cancer, 7, 2093, 10.7150/jca.16178 · DOI
  94. Mujumdar, 2010, Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways, Gastroenterology, 139, 598, 10.1053/j.gastro.2010.04.046 · DOI
  95. Chen, 2014, Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway, Cancer Lett., 348, 156, 10.1016/j.canlet.2014.03.016 · DOI
  96. Song, 2019, Triptolide attenuates lipopolysaccharide-induced inflammatory responses in human endothelial cells: involvement of NF-κB pathway, BMC Complement. Altern. Med., 19, 198, 10.1186/s12906-019-2616-3 · DOI

Cited by

Sorted by citations

See all 64

Metadata

Authors
Ren, Q., Li, M., Deng, Y., Lu, A., & Lu, J.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2021-03
Volume
165
Pages
105377
ISSN
1043-6618
DOI
10.1016/j.phrs.2020.105377
Cited by
64
References
1
Language
en
Licence
Funders
  • Shenzhen Scientific and Technological Foundation
  • National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review